Gold Prices Fall as Stronger Dollar, Fed Rate Outlook Weigh 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Asian Currencies Slip as Dollar Rebounds on Iran Sanctions 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Gold Prices Hover Near Three-Month High as Oil, Treasury Yields Fall 
Asian Currencies Mixed as Dollar Holds Firm Ahead of Jackson Hole 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Asian Stocks Slip Ahead of Nvidia Earnings and US Inflation Data 
US Stocks Finish Flat as Inflation Data, Nvidia Earnings Keep Investors Cautious 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Oil Prices Slide on U.S.-Iran Ceasefire Reports, Hormuz Talks 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Asian Chip Stocks Mixed After Nvidia Earnings Beat 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Add as a preferred source on Google
Lotte Biologics is allocating fresh investments in its own home ground to build three new production plants. The leading pharma company is spending $3 billion for the new facilities that will be constructed in South Korea.
Lotte Biologics is aiming to complete the new factories by the year 2030, and the plan is to build a bio-industrial complex where it will house the three plants. The company is expecting a production capacity of 360,000 liters of anti-body medicines per year in Korea.
As per Pulse News, Lotte Biologic’s chief executive officer, Lee Won Jik, revealed the company’s mid and long-term plan when he attended the J.P. Morgan Healthcare Conference in San Francisco. At that time, he said that they would bolster their business competitiveness to become a major competitor in the contract development and manufacturing organization (CDMO) market. The company’s strategy to achieve this is to acquire assets and build new facilities.
To set its plan in motion, the firm will start the construction of its first plant in the Lotte Bio Campus production complex within the second half of this year. This first factory is set to operate for commercial production by 2027. As for the entire complex, it is expected to be completed in 2034.
Lotte Biologics planned this new investment after completing its acquisition of Bristol Myers Squibb’s manufacturing plant in Syracuse, New York. It purchased the facility for $160 million earlier this month as part of its strategy to expand overseas.
“Each plant will require approximately $1 billion in investment for a total of $3 billion invested by 2030,” Lee said during the presentation. The three plants will each have a 120,000-liter capacity, for a combined 360,000 liters.” Korea Joongang Daily quoted Lotte Biologics’ CEO as saying during the conference with regards to its latest investment in South Korea.
He added, “While the locations have not been announced, the bio company plans to start the construction of the first plant in the second half of this year. The first plant is set to start commercial manufacturing in 2027 after completing the facility in the second half of 2025. It aims to run all of three factories by 2034 and generate $3 billion in sales annually with a profit margin of 35 percent.”
